Publications by authors named "M Oxoby"

Claim this Profile
V
Vectorization efforts to increase Gram-negative intracellular drug concentration: a case study on HldE-K inhibitors.
Dmytro Atamanyuk, Fabien Faivre, Mayalen Oxoby, Benoit Ledoussal, Elodie Drocourt

J Med Chem· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel HldE-K inhibitors leading to attenuated Gram negative bacterial virulence.
Nicolas Desroy, Alexis Denis, Chrystelle Oliveira, Dmytro Atamanyuk, Sophia Briet, Mayalen Oxoby

J Med Chem· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
Vincent Gerusz, Alexis Denis, Fabien Faivre, Yannick Bonvin, Mayalen Oxoby

J Med Chem· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
S Escaich, L Prouvensier, M Saccomani, L Durant, M Oxoby

Antimicrob Agents Chemother· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic synthesis of inhibitors of the two first enzymes of the bacterial heptose biosynthetic pathway: towards antivirulence molecules targeting lipopolysaccharide biosynthesis.
Maxime Durka, Abdellatif Tikad, Régis Périon, Michael Bosco, Mounir Andaloussi, Mayalen Oxoby

Chemistry· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis